About the Company
prometheus biosciences, inc., is a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $RXDX News
Prometheus Biosciences, Inc. (RXDX) is a Great Momentum Stock: Should You Buy?
Below, we take a look at Prometheus Biosciences, Inc. (RXDX), a company that currently holds a Momentum Style Score of B. We also talk about price change and earnings estimate revisions ...
Merck fires up a $10.8bn Prometheus takeover bid
Merck & Co has reached an agreement to buy Prometheus Biosciences in a $200-per-share cash transaction that values the San Diego-based biotech at $10.8 billion. The main object of the takeover is ...
10 Biotech Stocks with Huge Potential
agreement to acquire Seagen Inc. (NASDAQ:SGEN) in a $43 billion transaction, acquisition of Prometheus Biosciences, Inc.
Precision-driven Mirador launches with a $400M financing
The company plans to develop precision medicines using its engine for genetic profiling. The company was founded by former Prometheus Biosciences Inc. CEO Mark McKenna. Merck & Co. Inc. bought ...
Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations
IPO news flow returned, with Prometheus Biosciences, Inc. Common Stock (NASDAQ: RXDX), a biopharma focusing on therapies for inflammatory bowel disease, and Longboard Pharmaceuticals, Inc. Common ...
Mirador Therapeutics
The startup’s management includes several from the executive team of Prometheus Biosciences, an immunology biotech bought by Merck last year. Health tech executives shared how their companies ...
APTO Aptose Biosciences Inc.
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States.
HRMY Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the ...
Cormorant Private Healthcare Fund III LP's Net Worth
Who is Cormorant Private Healthcare Fund III LP? Cormorant Private Healthcare Fund III LP has an estimated net worth of $767 Million. This is based on reported shares across multiple companies ...
Harvard Bioscience Inc HBIO
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Forte Biosciences Inc.
Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic ...
10 Biotech Stocks with Huge Potential
agreement to acquire Seagen Inc. (NASDAQ:SGEN) in a $43 billion transaction, acquisition of Prometheus Biosciences, Inc. (NASDAQ:RXDX) by Merck & Co., Inc. (NYSE:MRK) for $10.8 billion, and AbbVie Inc ...
Loading the latest forecasts...